Story perspectives
FDA Approves Dawnzera: 81% Attack Reduction for HAE
8/22/2025
38 8
1 of 1
Story summary
- Ionis Pharmaceuticals gained FDA approval for Dawnzera, a drug aimed at preventing swelling attacks in hereditary angioedema (HAE).
- Clinical trials demonstrated an 81% reduction in monthly attacks.
- The drug will be priced at $57,462 per dose and is self-administered via injection every four to eight weeks.
- Approximately 7,000 patients in the U.S. are affected by HAE.
